

DALLAH HEALTHCARE COMPANY
(A Saudi Joint Stock Company)
**CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (UNAUDITED)**
For the three-month and nine-month periods ended 30 September 2022
together with the
INDEPENDENT AUDITORS' REVIEW REPORT

DALLAH HEALTHCARE COMPANY
A Saudi Joint Stock Company
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

CONTENTS	Page(s)
Independent Auditors' report on review of condensed consolidated interim financial statements	1-2
Condensed Consolidated Interim Financial Statements:	
Condensed consolidated statement of financial position	3
Condensed consolidated statement of profit or loss	4
Condensed consolidated statement of comprehensive income	5
Condensed consolidated statement of changes in equity	6
Condensed consolidated statement of cash flows	7
Notes to the condensed consolidated interim financial statements	8-25



KPMG Professional Services

Riyadh Front, Airport Road
P. O. Box 92876
Riyadh 11663
Kingdom of Saudi Arabia
Commercial Registration No 1010425494

Headquarters in Riyadh

كي بي إم جي للاستشارات المهنية

واجهة الرياض، طريق المطار
صندوق بريد ٩٢٨٧٦
الرياض ١١٦٦٣
المملكة العربية السعودية
سجل تجاري رقم ١٠١٠٤٢٥٤٩٤

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Dallah Healthcare Company (Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 30 September 2022 condensed consolidated interim financial statements of **Dallah Healthcare Company** ("the Company") and its subsidiaries ("the Group") which comprise:

- the condensed consolidated statement of financial position as at 30 September 2022;
- the condensed consolidated statement of profit or loss for the three-month and nine-month periods ended 30 September 2022;
- the condensed consolidated statement of comprehensive income for the three-month and nine-month periods ended 30 September 2022;
- the condensed consolidated statement of changes in equity for the nine-month period ended 30 September 2022;
- the condensed consolidated statement of cash flows for the nine-month period ended 30 September 2022; and
- the notes to the condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Dallah Healthcare Company (Saudi Joint Stock Company) (continued)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 September 2022 condensed consolidated interim financial statements of **Dallah Healthcare Company** and its subsidiaries are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPMG Professional Services

Fahad Mubark Aldossari
License No. 469



Riyadh on: 14 Rabi' II 1444H
Corresponding to: 08 November 2022

DALLAH HEALTHCARE COMPANY
A SAUDI JOINT STOCK COMPANY
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 September 2022
(All amounts in Saudi Riyals unless otherwise stated)

		30 September 2022 (Unaudited)	31 December 2021 (Audited)
	Notes		
ASSETS			
Non-current assets:			
Property and equipment	5	2,798,416,099	2,767,585,394
Right-of-use assets	6	38,274,532	29,999,757
Intangible assets and goodwill	7	204,312,092	195,217,282
Equity-accounted investees	8	208,487,882	185,909,586
Financial assets at fair value through other comprehensive income		296,073,774	292,125,416
Non-current assets		3,545,564,379	3,470,837,435
Current assets:			
Inventories	11	248,005,709	219,200,468
Unbilled revenue		33,530,642	12,861,982
Due from related parties	9	5,783,034	3,397,201
Trade receivables	10	732,044,863	625,116,646
Prepayments and other current assets		127,959,339	105,616,685
Cash and cash equivalents	12	341,164,620	208,079,114
Current assets		1,488,488,207	1,174,272,096
TOTAL ASSETS		5,034,052,586	4,645,109,531
EQUITY AND LIABILITIES			
Equity:			
Share capital	1	900,000,000	900,000,000
Share premium		61,142,305	61,142,305
Statutory reserve		66,168,590	66,168,590
Retained earnings		945,841,421	839,816,644
Fair value reserve		3,328,561	(336,969)
Equity attributable to owners of the Company		1,976,480,877	1,866,790,570
Non-controlling interests		241,858,881	229,285,247
Total Equity		2,218,339,758	2,096,075,817
LIABILITIES			
Non-current liabilities:			
Long-term murabaha financing	13	1,457,648,717	1,364,373,860
Long-term lease liabilities		20,522,764	10,742,375
Employee benefits		262,772,930	246,983,115
Long-term payable		3,418,398	3,504,423
Non-current liabilities		1,744,362,809	1,625,603,773
Current liabilities:			
Current portion of long-term murabaha financing	13	263,511,421	282,989,323
Short-term murabaha financing	13	265,349,032	219,998,068
Short-term lease liabilities		9,673,309	11,178,732
Short-term retentions		4,236,912	15,481,313
Trade payables		222,627,355	222,270,206
Due to a related parties	9	499,432	858,010
Accrued expenses and other current liabilities		177,794,046	146,819,426
Dividend payable	16	90,000,000	--
Provision for zakat	17	37,658,512	23,834,863
Current liabilities		1,071,350,019	923,429,941
TOTAL LIABILITIES		2,815,712,828	2,549,033,714
TOTAL EQUITY AND LIABILITIES		5,034,052,586	4,645,109,531

The accompanying notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the three-month and nine-month periods ended 30 September 2022

(All amounts in Saudi Riyals unless otherwise stated)

		For the three-month period ended 30 September		For the nine-month period ended 30 September	
		2022 (Unaudited) SR	2021 (Unaudited – Refer note 19) SR	2022 (Unaudited) SR	2021 (Unaudited – refer note 19) SR
	<i>Notes</i>				
Revenue	14	600,888,447	544,116,073	1,794,106,954	1,529,610,895
Cost of sales		(389,421,149)	(351,654,252)	(1,138,813,370)	(992,153,679)
Gross profit		211,467,298	192,461,821	655,293,584	537,457,216
Selling and marketing expenses		(11,499,015)	(11,700,327)	(32,887,893)	(28,558,063)
General and administrative expenses		(116,484,276)	(109,877,114)	(327,681,824)	(288,064,787)
Impairment reversal / (charge)		707,103	(938,221)	(3,929,016)	(9,403,139)
Operating profit		84,191,110	69,946,159	290,794,851	211,431,227
Other income, net		6,923,092	6,289,113	16,354,029	17,024,978
Finance cost		(19,401,773)	(9,106,535)	(44,999,002)	(26,934,683)
Share of results from investment in associates	8	(6,313,347)	(10,955,142)	(24,236,704)	(30,469,366)
Profit before zakat		65,399,082	56,173,595	237,913,174	171,052,156
Zakat	17	(17,744,318)	(4,539,372)	(29,314,763)	(14,471,385)
Profit for the period		47,654,764	51,634,223	208,598,411	156,580,771
Profit attributable to:					
Owners of the Company		43,873,221	49,850,162	196,024,777	150,003,204
Non-controlling interests		3,781,543	1,784,061	12,573,634	6,577,567
		47,654,764	51,634,223	208,598,411	156,580,771
Earnings per share:					
Basic and diluted earnings per share	15	0.49	0.55	2.18	1.67

The accompanying notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three-month and nine-month periods ended 30 September 2022

(All amounts in Saudi Riyals unless otherwise stated)

	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2022 (Unaudited)	2021 (Unaudited – Refer note 19)	2022 (Unaudited)	2021 (Unaudited – Refer note 19)
Profit for the period	<u>47,654,764</u>	<u>51,634,223</u>	<u>208,598,411</u>	<u>156,580,771</u>
Other comprehensive income:				
<i>Items that will not be reclassified to profit or loss</i>				
Change in valuation of financial assets at fair value through other comprehensive income	<u>27,819</u>	<u>45,434</u>	<u>3,665,530</u>	<u>55,388</u>
Other comprehensive income for the period	<u>27,819</u>	<u>45,434</u>	<u>3,665,530</u>	<u>55,388</u>
Total comprehensive income for the period	<u>47,682,583</u>	<u>51,679,657</u>	<u>212,263,941</u>	<u>156,636,159</u>
Total comprehensive income attributable to:				
Owners of the company	<u>43,901,040</u>	<u>49,895,596</u>	<u>199,690,307</u>	<u>150,058,592</u>
Non-controlling interests	<u>3,781,543</u>	<u>1,784,061</u>	<u>12,573,634</u>	<u>6,577,567</u>
	<u>47,682,583</u>	<u>51,679,657</u>	<u>212,263,941</u>	<u>156,636,159</u>

The accompanying notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the nine-month period ended 30 September 2022

(All amounts in Saudi Riyals unless otherwise stated)

	Attributable to owners of the Company						
	Share capital	Share premium	Statutory reserve	Retained earnings	Fair value reserve	Total shareholders' equity	Non-controlling interests
As at 1 January 2022	900,000,000	61,142,305	66,168,590	839,816,644	(336,969)	1,866,790,570	229,285,247
Profit for the period	--	--	--	196,024,777	--	196,024,777	12,573,634
Other comprehensive income for the period	--	--	--	--	3,665,530	3,665,530	--
Total comprehensive income for the period	--	--	--	196,024,777	3,665,530	199,690,307	12,573,634
Dividends (refer note 16)	--	--	--	(90,000,000)	--	(90,000,000)	--
As at 30 September 2022	900,000,000	61,142,305	66,168,590	945,841,421	3,328,561	1,976,480,877	241,858,881
As at 1 January 2021	900,000,000	61,142,305	40,308,478	793,517,078	(392,357)	1,794,575,504	213,454,771
Profit for the period (refer note 19)	--	--	--	150,003,204	--	150,003,204	6,577,567
Other comprehensive income for the period	--	--	--	--	55,388	55,388	--
Total comprehensive income for the period	--	--	--	150,003,204	55,388	150,058,592	6,577,567
Dividends	--	--	--	(67,500,000)	--	(67,500,000)	--
Changes in ownership interests	--	--	--	--	--	--	--
Movement in non-controlling interest	--	--	--	--	--	--	--
As at 30 September 2021	900,000,000	61,142,305	40,308,478	876,020,282	(336,969)	1,877,134,096	220,032,338
							2,097,166,434

The accompanying notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the nine-month period ended 30 September 2022

(All amounts in Saudi Riyals unless otherwise stated)

	<i>Notes</i>	For the nine-month period ended	
		30 September	
		2022	2021
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Profit before zakat		237,913,174	171,052,156
<i>Adjustments for:</i>			
Depreciation on property and equipment	5	74,085,031	73,603,808
Depreciation on right-of-use assets	6	13,011,954	12,886,658
Amortization on intangible assets	7	2,418,806	171,203
Employee benefits charge		32,302,588	33,222,037
Provision on obsolete and slow-moving inventory	11	54,149	2,675,597
Impairment loss on trade receivables	10	3,929,016	9,403,139
Loss on sale of property and equipment		19,518	126,060
Share of results from equity accounted investees	8	24,236,704	30,469,366
Finance cost		44,999,002	26,934,683
<i>Changes in operating assets and liabilities:</i>			
Trade receivables		(110,857,233)	(65,923,076)
Unbilled revenue		(20,668,660)	(12,962,893)
Related parties, net		(2,744,411)	(4,911,865)
Prepayments and other current assets		(22,342,654)	(5,511,147)
Inventories		(28,859,390)	(61,570,157)
Trade payables		357,149	32,681,624
Accrued expenses and other current liabilities		30,974,620	7,056,270
Contract liabilities		—	25,061,540
Short term retentions		(11,244,401)	(14,451,033)
Cash generated from operating activities		267,584,962	260,013,970
Zakat paid	17	(15,491,114)	(11,540,520)
Employees' benefits paid		(16,512,772)	(18,488,346)
Net cash generated from operating activities		235,581,076	229,985,104
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of property and equipment	5	(106,053,429)	(68,491,749)
Acquisition of intangible assets	7	(288,000)	(70,000)
Proceeds from the disposal of property and equipment		1,118,175	53,558
Additional capital contribution in associate	8	(46,815,000)	(21,846,512)
Acquisition of investment at fair value through other comprehensive income		(282,828)	--
Goodwill paid on acquisition of business	7	(11,225,616)	--
Dividends received		--	680,000
Net cash used in investing activities		(163,546,698)	(89,674,703)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Proceeds from murabaha finance	13	470,434,546	285,687,689
Repayment of murabaha finance	13	(351,286,627)	(284,186,645)
Payment of lease liabilities		(13,644,800)	(9,524,131)
Dividend paid		--	(27,500,000)
Long-term payable		(86,025)	--
Finance cost paid		(44,365,966)	(25,532,914)
Net cash generated from / (used) in financing activities		61,051,128	(61,056,001)
Net change in cash and cash equivalents		133,085,506	79,254,400
Cash and cash equivalents at beginning of the period		208,079,114	130,644,422
Cash and cash equivalents at end of the period	12	341,164,620	209,898,822

The accompanying notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

1. REPORTING ENTITY

Dallah Healthcare Company (the "Company") was a Limited Liability Company, registered in the Kingdom of Saudi Arabia under commercial registration number 1010128530 dated 13 Rabi Al-Akhar 1415H (corresponding to 18 September 1994).

The Company's Board of Directors declared Dallah Healthcare Company as a Saudi Public Joint Stock Company on 14 Jumada Al-Awwal 1429H (corresponding to 20 May 2008). The Company became a listed Company in the Saudi Capital Market Authority on 04 Safar 1434H (corresponding to 17 December 2012). The Company changed its name from "Dallah Healthcare Holding Company" to "Dallah Healthcare Company" based on the approval of the Extraordinary General Assembly held on 16 Safar 1438H (corresponding to 16 November 2016) after the completion of all legal formalities.

The objectives of the Company are to operate, manage and maintain the healthcare entities, wholesale medicines and retail of medical and surgical equipment, prosthetics and devices for the disabled, hospital equipment and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants and packaging in the Kingdom of Saudi Arabia.

Share Capital

The authorized, issued and paid up share capital of the Company is SR 900 million (31 December 2021: SR 900 million) consisting of 90 million shares of SR 10 each.

On 25 Muharram 1442H corresponding to 13 September 2020, the Extraordinary General Assembly meeting approved to increase the Company's capital from SR 750 million to SR 900 million (75 million shares to 90 million shares). As a result, the capital was increased by transferring SR 150 million from share premium to the capital. The Company amended its Article of Association accordingly.

The Group has the following branches:

Description	Commercial Registration No.	City
Head Office (Branch of Dallah Healthcare Co.)	2057004206	Al Khafji
Dallah Hospital Al-Nakheel	1010132622	Riyadh
Dallah Pharma Factory (Dallah Pharma Branch)	4030278471	Jeddah
Medicine Warehouse (Dallah Pharma Branch)	2050071905	Dammam
Medicine Warehouse (Dallah Pharma Branch)	1010128997	Riyadh
Medicine Warehouse (Dallah Pharma Branch)	4030140769	Jeddah
Medicine Warehouse (Dallah Pharma Branch)	4030265250	Jeddah

The Company's registered office is located at the following address:

King Fahad Road

Riyadh

Kingdom of Saudi Arabia

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

2. BASIS OF ACCOUNTING**a) *Statement of compliance***

These condensed consolidated interim financial statements comprise the interim financial statements of the Company and its subsidiaries (together referred to as the 'Group').

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' that are endorsed in the Kingdom of Saudi Arabia (KSA) and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants (SOCPA).

The condensed consolidated interim financial statements do not include all of the information and disclosures required for full annual consolidated financial statements and should be read in conjunction with Group's last annual consolidated financial statements as at and for the year ended 31 December 2021. Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements.

b) *Basis of preparation*

These condensed consolidated interim financial statements have been prepared on a going concern basis under the historical cost convention except for the provision for employees' end of service benefits which are measured at present value using projected unit credit method; and financial assets at fair value through other comprehensive income which are measured at fair value

c) *Functional and presentation currency*

These condensed consolidated interim financial statements are presented in Saudi Arabian Riyals (SR) which is also the Group's functional and presentational currency.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

2. BASIS OF ACCOUNTING (CONTINUED)**d) Basis of consolidation**

The subsidiary companies (referred to as the “Subsidiaries”) incorporated into these condensed consolidated interim financial statements are as follows:

Name of subsidiaries	Share in equity%		Country of operation and commercial register	Principal activity as per commercial registration	Capital (SR)
	As at 30 September 2022	As at 31 December 2021			
Dallah Pharma Company	100%	100%	Kingdom of Saudi Arabia, commercial registration No.1010410613	Pharmaceutical, herbal and cosmetic distribution and manufactory.	4,000,000
Afyaa Al-Nakheel for Supporting Services Company Limited	100%	100%	Kingdom of Saudi Arabia, commercial registration No.1010404576	Provide manpower and Support services to hospitals and medical centres.	50,000
Dallah Namar Hospital Health Company	100%	100%	Kingdom of Saudi Arabia, commercial registration No.1010495218	Operating, managing, equipping and developing hospitals and healthcare facilities, medical polyclinics.	5,000,000
Dallah Medical Care Company (previously known as Rafa Care Clinic Company)	100%	--	Kingdom of Saudi Arabia, Commercial Registration No. 1010189420	Providing of medical services – Medical Clinic	100,000
Care Shield Holding Company (Closed Joint Stock Company)**	58.64%	58.64%	Kingdom of Saudi Arabia, commercial registration No.1010379441	Managing private hospitals, medical and diagnostic centers, and an analytical laboratory, providing medical services, purchasing lands to build buildings on, and investing these buildings by sale or rent for the benefit of the company.	125,000,000
Makkah Medical Center Company (Closed Joint Stock Company)	89.36%	89.36%	Kingdom of Saudi Arabia, commercial registration No. 4031021286	Practicing the activity of public hospitals	120,080,000

** Care Shield Holding Company condensed consolidated interim financial statements include the Company and the following subsidiaries:

Subsidiaries**Care Shield Holding Company ownership %**

1. Medical Services Projects Company (“MSPC”)	100%
2. Consulting Clinics Center Company Limited (“CC”)	100%
3. Modern Clinics Pharmacy Company Limited (“MCP”)	100%

The basis of accounting in respect of business combination and goodwill, subsidiaries, non-controlling interests (NCI), loss of control, interests in equity-accounted investees and transactions eliminated on consolidation are consistent with those used and disclosed in detail in annual consolidated financial statements for the year ended 31 December 2021.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

3. USE OF JUDGEMENTS AND ESTIMATES

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

During the preparation of these condensed consolidated interim financial statements, there have been no changes in the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation and uncertainty from those which were applied to the annual audited consolidated financial statements of the Group for the year ended 31 December 2021.

The Group's financial risk management objectives and policies and the methods to determine the fair values are consistent with those disclosed in the most recent annual consolidated financial statements for the year ended 31 December 2021.

The Group follows the practice of performing actuarial valuations annually at the year end.

Measurement of fair values

A number of the Group's accounting policies require the measurement of fair values, for both financial and non-financial assets and liabilities. The Group has an established control framework with respect to the measurement of fair values. This includes a valuation team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values, and reports directly to the chief financial officer.

The valuation team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the valuation team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the Standards, including the level in the fair value hierarchy in which the valuations should be classified.

When measuring the fair value of an asset or a liability, the Group uses market observable data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability are categorised in different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

4. SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied and method of computation adopted for preparation of these condensed consolidated interim financial statements are consistent with those that were applied in the Group's last annual consolidated financial statements for the year ended 31 December 2021.

There are no new standards issued during the current period, however, a number of amendments to the standards are effective from 1 January 2022, which have been explained in the Group's last annual consolidated financial statements. These have no material impact on the Group's interim condensed consolidated financial statements.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

5. PROPERTY AND EQUIPMENT

	Land	Buildings	Leasehold Improvements	Machinery and Equipment	Medical Equipment	Furniture and Fixtures	Vehicles	Construction Work in Progress	Total
Cost:									
As at 1 January 2022	833,502,199	1,721,998,055	85,315,258	180,689,838	645,962,332	46,804,511	11,340,590	117,052,111	3,642,664,894
Additions	--	16,867,020	608,884	8,594,143	34,115,405	3,686,393	631,923	41,549,661	106,053,429
Disposals	--	--	(873,159)	(147,269)	(4,048,527)	(62,980)	(279,214)	--	(5,411,149)
Transfer in / (out)	--	3,318,861	--	--	--	--	--	(3,318,861)	--
As at 30 September 2022	833,502,199	1,742,183,936	85,050,983	189,136,712	676,029,210	50,427,924	11,693,299	155,282,911	3,743,307,174
Accumulated Depreciation:									
As at 1 January 2022	--	299,529,991	71,543,889	87,006,521	383,695,577	24,540,520	8,763,002	--	875,079,500
Charge for the period	--	23,869,390	1,255,316	8,310,669	37,215,800	2,910,042	523,814	--	74,085,031
Disposals	--	--	(618,850)	(146,472)	(3,247,329)	(46,591)	(214,214)	--	(4,273,456)
As at 30 September 2022	--	323,399,381	72,180,355	95,170,718	417,664,048	27,403,971	9,072,602	--	944,891,075
Net book value:									
As at 30 September 2022	833,502,199	1,418,784,555	12,870,628	93,965,994	258,365,162	23,023,953	2,620,697	155,282,911	2,798,416,099
As at 31 December 2021	833,502,199	1,422,468,064	13,771,369	93,683,317	262,266,755	22,263,991	2,577,588	117,052,111	2,767,585,394

5.1 Care Shield Holding Company ("CSHC") - LAND

The total value of the Kingdom Hospital land (registered under Medical Projects Services Company) is SR 46.7 million of which land of SR 35 million was acquired in 2012 (that is situated in the southern area of the hospital in front of its emergency department). The remainder of the hospital land capitalized is SR 11.7 million which includes a portion of the land measuring 11,856 square meters, consisting of blocks 584 and 585, under Legal Instrument No. 761/4 dated 03/05/1403 AH; for which the title of land was registered in the name of HRH Prince Alwaleed Bin Talal as at 31 December 2021. On 15 February 2022 corresponding to 14 Rajab 1443H, the title deed of this land was transferred in the name of Medical Services Projects Company ("MSPC") after completing all the legal formalities.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

6. RIGHT OF USE ASSETS

	30 September 2022	31 December 2021
<u>Cost:</u>		
Balance at the beginning of the period/year	63,982,850	51,243,157
Additions to right of use assets	10,319,347	21,469,950
Adjustment	--	2,038,180
Acquisition of business (note 7.3)	12,989,541	--
De-recognition of right of use assets	(12,265,579)	(10,768,437)
Balance at end of the period/year	75,026,159	63,982,850
<u>Accumulated Depreciation:</u>		
Balance at beginning of the period/year	33,983,093	26,587,101
Depreciation charge for the period/year	13,011,954	17,934,495
De-recognition of right of use assets	(10,243,420)	(10,538,503)
Balance at end of the period/year	36,751,627	33,983,093
Net book value	38,274,532	29,999,757

Right-of-use assets include rentals for buildings for workers' accommodation. The rentals are for an average lease term of 3-4 years and lease payments are fixed.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

7. INTANGIBLE ASSETS AND GOODWILL

	Goodwill	Manufacturing licenses	Product licenses	Brand	License	Programs	Total
Cost:							
At 1 January 2022 (note 7.1 and 7.2)	109,915,614	10,648,000	11,505,000	30,900,000	49,100,000	402,450	212,471,064
Additions	--	--	--	--	--	288,000	288,000
Acquisition of business (note 7.3)	11,225,616	--	--	--	--	--	11,225,616
As at 30 September 2022	121,141,230	10,648,000	11,505,000	30,900,000	49,100,000	690,450	223,984,680
Amortization and Impairment:							
At 1 January 2022	5,091,000	4,529,600	4,701,000	1,132,083	1,739,583	60,516	17,253,782
Charge for the period	--	191,199	212,625	772,497	1,227,502	14,983	2,418,806
As at 30 September 2022	5,091,000	4,720,799	4,913,625	1,904,580	2,967,085	75,499	19,672,588
Net book value:							
As at 30 September 2022	116,050,230	5,927,201	6,591,375	28,995,420	46,132,915	614,951	204,312,092
As at 31 December 2021	104,824,614	6,118,400	6,804,000	29,767,917	47,360,417	341,934	195,217,282

7.1 Goodwill includes SR 5.09 million pertaining to Dallah Pharma Company which has been fully impaired in the year 2016.

7.2 Goodwill also includes SR 104.82 million recognised on acquisition of 58.64% stake of Care Shield Holding Company in November 2020.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

7. INTANGIBLE ASSETS AND GOODWILL (CONTINUED)**7.3 Goodwill on acquisition of Dallah Medical Care Company (previously known as Rafa Care Clinic Company)**

On 12 Ramadan 1443H (corresponding to 13 April 2022), the Company signed a final agreement to acquire the business of Dallah Medical Care Company for SR 12 million, representing 100% of its shares. The Company has performed a preliminary assessment of the assets and liabilities of Dallah Medical Care Company. As a result, goodwill amounting to SR 11.22 million was recognized according to the provisional amount of assets and liabilities of the Company acquired on the date of acquisition due to the incomplete study of the allocation of the purchase price. As per the final agreement, the liability of the Company on acquisition of the business is restricted to SR 3.1 million. The Company is in the process of conducting a detailed assessment of the fair values of the assets, liabilities and customer listing acquired. Clinic is now operating under the brand name of Dallah Healthcare.

	30 September 2022
Consideration paid	12,000,000
Provisional value of net assets acquired at acquisition date <i>*(refer "a" below)</i>	(774,384)
Goodwill	11,225,616

*The following table summarises the recognised provisional amounts of assets acquired and liabilities assumed at the date of acquisition.

	As on 30 September 2022
Property and equipment (net book value)	3,905,551
Right of use assets	12,989,541
Inventories	158,166
Lease liabilities	(13,181,912)
Trade payables and other liabilities	(3,096,962)
Total provisional net assets acquired at acquisition date	774,384

8. EQUITY ACCOUNTED INVESTEEES

Equity accounted investee comprises as follows:

	Ownership interest in equity as at 30 September 2022	Ownership interest in equity as at 31 December 2021	Country of operation and principal place of business	30 September 2022	31 December 2021
Dr. Mohammed Rashid Al-Faqih Company	31.21%	31.21%	Kingdom of Saudi Arabia	114,944,101	95,403,018
Meraas Arabia Medical Holding Company**	17%	17%	Kingdom of Saudi Arabia	42,940,934	39,903,721
MEFIC Private Equity Opportunities Fund 3	41.6%	41.6%	Kingdom of Saudi Arabia	50,602,847	50,602,847
				208,487,882	185,909,586

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

8. EQUITY ACCOUNTED INVESTEEES (CONTINUED)

** The total percentage direct and indirect ownership holding of Dallah Healthcare Company in Meraas Arabia Medical Holding Company is 35%. The investment is equity accounted as the Group has significant influence due to common directorship.

i) Dr. Mohammed Rashid Al-Faqih Company

The principal activity of Dr. Mohammed Rashid Al-Faqih Company is to own, operate and maintain the hospitals and health centres. Dr. Mohammed Rashid Al-Faqih Company owns a hospital in eastern Riyadh City under the name of Dr. Muhammad Al-Faqih Hospital.

On 13 Muharram 1442H (corresponding to 1 September 2020), the operation of the first phase of the hospital began. The hospital has a capacity of 308 beds. Management expects losses during the first two years as a result of the start-up costs.

The movement in equity-accounted investment is as follows:

	30 September 2022	31 December 2021
Balance at the beginning of the period / year	95,403,018	119,447,616
Group's share of loss	(27,273,917)	(45,985,053)
Additional capital contribution	46,815,000	21,846,512
Group's share of other comprehensive income	--	93,943
Balance at the end of the period / year	<u>114,944,101</u>	<u>95,403,018</u>

The aggregate amounts of certain financial information of the associate can be summarized as follows:

	30 September 2022	31 December 2021
Current assets	221,682,566	94,214,812
Non-current assets	764,330,779	779,944,533
Current liabilities	94,822,319	107,580,993
Non-current liabilities	567,275,097	505,274,034
Loss from continuing operations	(87,388,392)	(147,340,767)
Other comprehensive income	--	301,002
Equity	323,915,929	261,304,318

	30 September 2022	31 December 2021
Net assets	323,915,929	261,304,318
Percentage ownership with the group	31.21%	31.21%
Ownership of net assets with the group	101,094,161	81,553,078
Goodwill	13,849,940	13,849,940
Carrying amount of interest in associate	<u>114,944,101</u>	<u>95,403,018</u>

ii) MERAS Arabia Medical Holding Company

In February 2020, Dallah Healthcare Company purchased 17% of the ownership investment of MERAS Arabia Medical Holding Company, and recorded investment at fair value through profit and loss.

On 31 August 2020, Dallah Healthcare Company achieved significant influence over Meras Al Arabia Holding Company, therefore the investment was classified as an investment in associate and recorded at fair value at that date amounting to SR 37,103,731.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

8. EQUITY ACCOUNTED INVESTEEES (CONTINUED)**ii) MERAS Arabia Medical Holding Company (continued)**

The movement in equity-accounted investment is as follows:

	30 September 2022	31 December 2021
Balance at the beginning of the period / year	39,903,721	37,564,043
Group's share of profit	3,037,213	2,625,443
Group share of result from comprehensive income	--	394,235
Dividends received	--	(680,000)
Balance at the end of the period / year	42,940,934	39,903,721

The aggregate amounts of certain financial information of the associate can be summarized as follows:

	30 September 2022	31 December 2021
Current assets	45,452,221	30,022,621
Non-current assets	125,964,156	127,488,408
Current liabilities	42,629,616	65,053,687
Non-current liabilities	48,051,589	29,588,128
Profit or loss from continuing operation	17,865,958	15,443,784
Comprehensive income	--	2,319,032
Equity	80,735,172	62,869,214
	30 September 2022	31 December 2021
Net assets	80,735,172	62,869,214
Percentage ownership with the group	17%	17%
Ownership of net assets with the group	13,724,979	10,687,766
Goodwill	29,215,955	29,215,955
Carrying amount of interest in associate	42,940,934	39,903,721

iii) MEFIC Private Equity Opportunities Fund 3

As of 16 Jumada Al-Awwal 1442H (corresponding to 31 December 2021) the Group owns 41.6% of the units of the MEFIC Private Equity Opportunities Fund 3, the objective of the fund is to achieve a high return on capital in the long term and to invest in the health sector.

The movement in equity-accounted investment is as follows:

	30 September 2022	31 December 2021
Balance at the beginning of the period / year	50,602,847	38,319,354
Group's share of profit	--	12,283,493
Balance at the end of the period / year	50,602,847	50,602,847

9. RELATED PARTIES BALANCES

Related parties of the Group comprise of key management personnel and associates where shareholders have control or significant influence. The Group and its related parties transact with each other as per mutually agreed terms as approved by the management of the Group.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

9. RELATED PARTIES BALANCES (CONTINUED)**Name of related parties:**

Dallah Al-Barakah Holding
 Dr Mohammed Rashid Al-Faqih Company
 Al-Mashfa Medical
 Adaptive TechSoft
 Dareen Travel Agency
 Eng. Tarek Alkasabi
 Dr. Khalid Al-Faqih

Relationship:

Shareholder
 Associate company
 Close family member
 Owned partially by shareholder
 Owned partially by shareholder
 Chairman of Board
 Close family member

i) Due from related parties

	30 September 2022	31 December 2021
Dr Mohammed Rashid Al-Faqih Company	4,292,029	2,766,839
Al-Mashfa Medical	732,364	328,014
Adaptive techsoft	408,820	--
Dallah Al-Barakah Holding	283,473	302,348
Others	66,348	--
	5,783,034	3,397,201

ii) Due to related parties

	30 September 2022	31 December 2021
Dareen Travel Agency	499,432	814,020
Adaptive Techsoft	--	20,700
Others	--	23,290
	499,432	858,010

10. TRADE RECEIVABLES

	30 September 2022	31 December 2021
Trade receivables	894,841,129	756,682,043
Refund liability	(83,244,172)	(55,942,319)
Net trade receivables	811,596,957	700,739,724
Impairment loss allowance (note 10.1)	(79,552,094)	(75,623,078)
	732,044,863	625,116,646

10.1. Movement in the allowance for impairment in respect of trade receivables during the period / year was as follows:

	Nine-month period ended 30 September 2022	Year ended 31 December 2021
Balance at the beginning of the period / year	75,623,078	62,233,775
Charge for the period/ year	3,929,016	17,104,441
Written-off during the period/ year	--	(3,715,138)
Balance at the end of the period / year	79,552,094	75,623,078

All of the above Group's trade receivables have been reviewed for indicators of impairment.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

11. INVENTORIES

	30 September 2022	31 December 2021
Medical supplies and pharmaceutical items	248,995,943	220,136,553
Provision for obsolete and slow-moving	(990,234)	(936,085)
	248,005,709	219,200,468

Movement in the provision of obsolete and slow-moving inventory during the period / year was as follows:

	Nine-month period ended 30 September 2022	Year ended 31 December 2021
Balance at beginning of the period / year	936,085	2,769,613
Charge/(reversal) during the period/ year	54,149	(1,297,620)
Written-off during the period/ year	--	(535,908)
Balance at the end of the period / year	990,234	936,085

12. CASH AND CASH EQUIVALENTS

	30 September 2022	31 December 2021
Cash at banks – current accounts (<i>note 12.1</i>)	338,600,089	206,571,961
Cash in hand	2,564,531	1,507,153
	341,164,620	208,079,114

12.1. This represents cash held in current accounts with banks operating in the Kingdom of Saudi Arabia.

13. MURABAHA FINANCING

	30 September 2022	31 December 2021
Non-current:		
Long-term murabaha financing	1,457,648,717	1,364,373,860
Current:		
Short-term murabaha financing	265,349,032	219,998,068
Current portion of long-term murabaha financing	263,511,421	282,989,323
Total short-term and current murabaha finance	528,860,453	502,987,391
Total murabaha financing	1,986,509,170	1,867,361,251

- i) The Group has Murabaha finance contracts with local banks. Murabaha contracts are denominated in Saudi Riyals and bear financial cost based on prevailing market price. Murabaha contracts are obtained to finance the construction of new medical facilities and hospitals under construction. Murabaha contracts are secured by promissory bonds.

Dallah Healthcare Company and its 100% owned subsidiaries as at 30 September 2022, have Murabaha available for use at an amount of SR 4,100 million (31 December 2021: SR 2,386 million), out of which an amount of SR 1,875 million was utilized as at 30 September 2022 (31 December 2021: SR 1,784 million), and secured by promissory notes as at 30 September 2022, with a total of SR 3,833 million (31 December 2021: SR 3,833 million).

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

13. MURABAHA FINANCING (CONTINUED)

On 25 Muharram 1443H (corresponding to 02 September 2021), the Group signed an agreement with Ministry of Finance to obtain long term loan amounting to SR 357 million for the period of 10 years (16 semi-annual installments) to support the Group's strategy in completing the construction of Dallah Namar Hospital. The long-term loan has been secured by two promissory notes and mortgage deed of land for Dallah Namar Hospital. Out of these loans SR 216 million has been received till 30 September 2022.

- ii) The Murabaha financing balance as at 30 September 2022, includes a loan pertains to Care Shield Holding Company, a "subsidiary company", amounting to SR 107.3 million, (31 December 2021: SR 79.5 million).

The balance of the Murabaha financing as of 30 September 2022 includes a loan pertains to Makkah Medical Centre Company, a "subsidiary company", amounting to about SR 3.9 million (31 December 2021: SR 3.9 million), which the company obtained from the Ministry of Finance, the loan is secured by a mortgage over the hospital's land, buildings on which it is built, medical and non-medical equipment and furniture and furnishings.

The financing cost recognized in the condensed consolidated interim statement of profit or loss during the nine-months ended 30 September 2022 includes murabaha financing cost amounted to SR 44.4 million (during the nine-months ended 30 September 2021: SR 25.5 million).

- iii) Movement summary of Murabaha financing is as follows:

	Nine-month period ended 30 September 2022	Year ended 31 December 2021
Balance at beginning of the period/ year	1,867,361,251	1,514,794,266
Proceeds during the period/ year	470,434,546	730,728,867
Payments made during the period/ year	(351,286,627)	(378,161,882)
Balance at end of the period/ year	<u>1,986,509,170</u>	<u>1,867,361,251</u>

14. REVENUE

	For the nine-months period ended 30 September 2022	2021
Revenue		
Revenue from services	1,384,683,998	1,165,473,074
Revenue from sale of medicine	<u>409,422,956</u>	<u>364,137,821</u>
	<u>1,794,106,954</u>	<u>1,529,610,895</u>
Timing of revenue recognition		
Services transferred over time	641,295,220	558,826,584
Products and services transferred at a point in time	<u>1,152,811,734</u>	<u>970,784,311</u>
	<u>1,794,106,954</u>	<u>1,529,610,895</u>

Revenue recorded during the period is net of rejections.

15. BASIC AND DILUTED EARNINGS PER SHARE

Basic earnings per share ("EPS") is calculated by dividing the profit for the period attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the period.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

15. BASIC AND DILUTED EARNINGS PER SHARE (CONTINUED)

The diluted earnings per share is same as the basic earnings per share as the Group does not have any dilutive equity instruments and as a result diluted EPS is equal to the basic EPS for the three-months and nine-month period ended 30 September 2022 and 30 September 2021.

	For the three-month period ended		For the nine-month period ended	
	30 September 2022	30 September 2021	30 September 2022	30 September 2021
Net profit for the period, attributable to owners of the Company	43,873,221	49,850,162	196,024,777	150,003,204
Weighted average number of ordinary shares	90,000,000	90,000,000	90,000,000	90,000,000
Basic and diluted earnings per share	0.49	0.55	2.18	1.67

The number of shares outstanding are 90 million shares, and earnings per share is calculated on the basis of the shares outstanding at 30 September 2022 and 30 September 2021.

16. DIVIDEND

On 25 Safar 1444H, (corresponding to 21 September 2022), and in accordance with the mandate of the Ordinary General Assembly of the Board of Directors to distribute interim dividends, the Board of Directors of the Company decided to distribute interim cash dividends to shareholders for the first half of the fiscal year 2022, in the amount of SR 90,000,000 at SAR 1 per share. The dividends have been paid subsequent to period end on 9 October 2022.

17. ZAKAT PROVISION

The following tables shows the details of movement of zakat provision as at the reporting date.

	30 September 2022	31 December 2021
Balance at the beginning of the period/year	23,834,863	18,052,591
Charge for the period/year	29,314,763	16,926,886
Payments made during the period/year	(15,491,114)	(11,144,614)
Balance at end of the period/year	37,658,512	23,834,863

The Group received zakat assessments for the years from 2014 until 2018, whereby additional demand of SR 19.7 million was made. The Group filed an appeal within the due date. ZATCA has raised certain additional queries for the years 2019 to 2020 in respect of additional zakat exposure of SR 26.6 million. These have been responded by the Group and ZATCA's review is awaited. Management, in consultation with the Zakat advisor has recognized a provision of SR 21.9 million in respect of open items.

18. CONTINGENCIES AND COMMITMENTS**Capital commitments**

As at 30 September 2022, the Group had capital commitments that mainly relate to construction contracts of the expansion of Dallah Hospital Al-Nakheel and the construction of Dallah Namar Hospital amounting to SR 85.12 million (31 December 2021: SR 157.7 million).

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

18. CONTINGENCIES AND COMMITMENTS (CONTINUED)**Contingent liabilities**

- i) As at 30 September 2022, the Group has potential liabilities in the form of bank guarantees amounting to SR 50 million issued on behalf of the Group in the ordinary course of business (31 December 2021: SR 44.4 million). The bank guarantees include a bank guarantee issued during the year 2018 to a third party on behalf of Dr. Muhammad Al-Faqih Company "an associate company" amounting to SR 17.5 million, expiring on 29 October 2022.
- ii) There are letters of credit issued by the Group amounting to SR 46.5 million as on 30 September 2022 (31 December 2021: SR 55.8 million).
- iii) The Group has certain cases with Zakat, Tax and Custom Authorities (ZATCA) related to disputed value added tax amounting to SR 7.42 million. Management is in consultation with their consultants, consider that they have a strong position in these cases which are under appeal in the General Secretariat of Tax committees (GSTC), and the Company has elected to contest the cases continuously, therefore, no provision is recognized in these condensed consolidated interim financial statements.
- iv) The Group has certain open appeals amounting to SR 24.4 million with ZATCA pertaining to years from 2014 to 2020. Management after consulting with zakat advisor consider that they have a strong position in these cases. Accordingly, no provision is recognized in these condensed interim financial statements.

19. CHANGES IN PRIOR PERIOD

During the three-month period ended 30 September 2021, an adjustment of SR 34.86 million was recognised upon finalization of the purchase price allocation exercise in relation to acquisition of Makkah Medical Centre which took place in December 2020. However, IFRS 3- Business Combination requires a retrospective adjustment to the provisional amounts recognized at the acquisition date. While finalizing the consolidated financial statements for the year ended 31 December 2021, the Group accounted for this as per the requirements of IFRS 3 and hence no adjustment was required for 31 December 2021. The error in the three and nine-months period ended 30 September 2021 has been corrected by adjusting each impacted financial statement line item. Accordingly, the gain from acquisition of subsidiary has been reduced by an amount of SR 34.86 million in the condensed consolidated interim statement of profit or loss for the three and nine-months period ended 30 September 2021 and the retained earnings as of 01 January 2021 has been increased by the same amount accordingly.

20. SUBSEQUENT EVENTS

No material events occurred subsequent to the reporting date, which could materially affect the condensed consolidated interim financial statements, and the related disclosures for the nine-month period ended 30 September 2022.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

21. OPERATING SEGMENTS

As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services and has two reportable segments.

Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the Chief Executive Officer as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments.

The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group.

The identified key segments are Medical Services/ Medicine and Pharmaceutical Products. Information regarding the Group's reportable segments is presented below:

Based on nature of services:

30 September 2022	Medical Services	Medicine and Pharmaceutical Products	Total
Revenue	1,692,020,949	102,086,005	1,794,106,954
Cost of revenue	(1,074,272,290)	(64,541,080)	(1,138,813,370)
Gross profit	617,748,659	37,544,925	655,293,584
Operating expenses	(332,328,144)	(32,170,589)	(364,498,733)
Operating profit	285,420,515	5,374,336	290,794,851
Other income, net	15,689,026	665,003	16,354,029
Finance cost	(44,657,279)	(341,723)	(44,999,002)
Share of results from equity accounted investees	(24,236,704)	--	(24,236,704)
Zakat	(29,128,419)	(186,344)	(29,314,763)
Net profit	203,087,139	5,511,272	208,598,411
As at 30 September 2022			
Total assets	4,848,324,705	185,727,881	5,034,052,586
Total liabilities	2,527,703,761	288,009,067	2,815,712,828

Geographical segments:

All of the Group's operating assets and principal markets of activity are located in the Kingdom of Saudi Arabia.

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2022 (Unaudited)

All amounts are presented in Saudi Riyals unless otherwise stated

22. FINANCIAL RISK MANAGEMENT

The risk management framework and policies of the Group are consistent with those used and disclosed in the annual consolidated financial statements of the Group for the year ended 31 December 2021.

23. DATE OF AUTHORIZATION

These condensed consolidated interim financial statements were authorized for issue by the Group's Board of Directors on 13 Rabi' II 1444H (Corresponding to 07 November 2022).